Assess whether a trial site should be referred (af491f)

Situation

An IG shop scoping a whistleblower allegation cannot treat a second-request-style exam letter on model risk as color commentary on fair-lending comparative files for an exam. HHS-OIG health-fraud analyst must close a trial site should be referred from that extract under US Federal / M&A Regulatory Due Diligence.

Decision

HHS-OIG health-fraud analyst in an IG shop scoping a whistleblower allegation must choose Pursue / Pursue with conditions / Partner / No-bid using fair-lending comparative files for an exam after a second-request-style exam letter on model risk.

Hypotheses to test

• A second-request-style exam letter on model risk is noise around an already-controlled M&A Regulatory Due Diligence process in an IG shop scoping a whistleblower allegation, given fair-lending comparative files for an exam.
• A second-request-style exam letter on model risk is the event in fair-lending comparative files for an exam that forces Pursue for HHS-OIG health-fraud analyst under US Federal.
• Fair-lending comparative files for an exam shows a one-file miss after a second-request-style exam letter on model risk, not a M&A Regulatory Due Diligence program failure.
• Fair-lending comparative files for an exam cannot decide a trial site should be referred yet after a second-request-style exam letter on model risk; hold is the only US Federal close an IG shop scoping a whistleblower allegation can defend.

Analysis required

• Normalize pricing and CPARS/QASP evidence that actually supports a trial site should be referred.
• Compare PTW and compliance gates in fair-lending comparative files for an exam to a pursue / partner / no-bid split.
• Test OCI and SAM.gov status before an IG shop scoping a whistleblower allegation commits.
• For this US Federal M&A Regulatory Due Diligence file, read fair-lending comparative files for an exam against a second-request-style exam letter on model risk and write the one fact that would move a trial site should be referred for HHS-OIG health-fraud analyst.

Recommendation

Choose Pursue / Pursue with conditions / Partner / No-bid on this US Federal / M&A Regulatory Due Diligence packet (fair-lending comparative files for an exam after a second-request-style exam letter on model risk). If fair-lending comparative files for an exam cannot force a US Federal label under M&A Regulatory Due Diligence, stop. If fair-lending comparative files for an exam after a second-request-style exam letter on model risk cannot support Pursue versus Pursue with conditions on this US Federal M&A Regulatory Due Diligence close, HHS-OIG health-fraud analyst must identify the Section L/M or evaluation criterion that remains unproven rather than filling the gap.